Therapeutic inertia related to the injectable glucagon‐like peptide‐1 receptor agonists dulaglutide and semaglutide in patients with type 2 diabetes in UK primary care
Authors' conclusion
Multiple examples of therapeutic inertia were identified, including first prescription at HbA1c levels considerably above target and failure to escalate to optimal doses even with evidence of suboptimal metabolic control. A substantial proportion of patients therefore did not achieve optimal HbA1c targets.
Study context
- Population
- Adults with T2D receiving first primary care prescription of dulaglutide or semaglutide, January–July 2019, UK
- Participants
- 748 vs 437
- Exposure
- Dulaglutide vs semaglutide
- Dulaglutiden = 748
- Semaglutiden = 437
- Outcome
- Extent of therapeutic inertia: doses prescribed, HbA1c, body mass index (BMI) and concomitant T2D medications
- Follow-up
- First prescription and 3, 6 and 9 months
Methodological detailsUK Clinical Practice Research Datalink GOLD primary care database
- UK Clinical Practice Research Datalink GOLD primary care database
Main finding
As reported in the abstract
HbA1c ≥7.5% (≥58.46 mmol/mol) at first prescription
Observational data: associations, not effects.
Further findings
HbA1c ≥9.0% (≥74.86 mmol/mol) at first prescription
HbA1c ≥7.5% (≥58.46 mmol/mol) among those on dulaglutide 0.75 mg or semaglutide 0.25 mg or 0.5 mg · 6 to 9 months
On suboptimal dose (dulaglutide 0.75 mg; semaglutide 0.25 mg or 0.5 mg) · 9 months
Original publication
Therapeutic inertia related to the injectable glucagon‐like peptide‐1 receptor agonists dulaglutide and semaglutide in patients with type 2 diabetes in UK primary care. Diabetes Obes Metab. Published 10 February 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →